Last reviewed · How we verify
COPPER OXODOTREOTIDE CU-64 — Competitive Intelligence Brief
marketed
Recombinant protein
Live · refreshed every 30 min
Target snapshot
COPPER OXODOTREOTIDE CU-64 (COPPER OXODOTREOTIDE CU-64).
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| COPPER OXODOTREOTIDE CU-64 TARGET | COPPER OXODOTREOTIDE CU-64 | marketed | 2020-01-01 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- COPPER OXODOTREOTIDE CU-64 CI watch — RSS
- COPPER OXODOTREOTIDE CU-64 CI watch — Atom
- COPPER OXODOTREOTIDE CU-64 CI watch — JSON
- COPPER OXODOTREOTIDE CU-64 alone — RSS
Cite this brief
Drug Landscape (2026). COPPER OXODOTREOTIDE CU-64 — Competitive Intelligence Brief. https://druglandscape.com/ci/copper-oxodotreotide-cu-64. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab